7 results about "Refractory epilepsy" patented technology

Disclosed are compounds of the formula (I) and pharmaceutically acceptable salts thereof, wherein Ring A, Ring B, R1, R2, R3, R12, and L are as defined herein. The compounds are antagonists of the resistant (R-type) voltage-gated calcium ion channel Cav 2.3. Also disclosed are pharmaceutical compositions comprising the compounds; and the compounds for use in the treatment of diseases modulated Cav 2.3, including epilepsy, neurodegenerative conditions such as Parkinson's disease, focal, drug-resistant forms of epilepsy, and other neurological disorders such as developmental and epileptic encephalopathies and Phelan-McDermid and Fragile X syndromes.

Systems, devices, and methods for treating drug-refractory epilepsy are disclosed. [Solution] In one embodiment, a method for treating epilepsy is disclosed, comprising detecting electrophysiological signals of a subject using a first electrode array coupled to a first intravascular carrier. The method further comprises analyzing the electrophysiological signals using a neuromodulator electrically coupled to the first electrode array, and stimulating a target site in the subject's body using a second electrode array coupled to a second intravascular carrier implanted in a portion of a body blood vessel above the base of the subject's skull.

The invention provides a neural stem cell induced differentiation and clinical application method for intractable epilepsy, and relates to the technical field of biological medicine, the induced differentiation method comprises the following steps: S1, cell source and preparation: adopting induced pluripotent stem cells from a patient; s2, constructing an induced differentiation system, differentiating the induced pluripotent stem cells into GABA (gamma-aminobutyric acid) inhibitory interneurons, and differentiating the GABA inhibitory interneurons; s3, purifying and amplifying the cells, adopting immunomagnetic bead sorting, and purifying and enriching the cells expressing the GABA energy neuron marker; s4, cell quality control; according to the method, the autologous induced pluripotent stem cells of the patient are taken as a source, immunological rejection is avoided, the transplanting safety is improved, and moreover, the high-purity GABAergic neurons can more effectively supplement damaged inhibitory neurons in the brain of the epileptic and reconstruct the inhibition balance of a neural network, so that the epileptic seizure is more effectively controlled.

The present application relates to the technical field of gene detection, in particular to a gene panel, method, device and use for somatic cell variation detection of SLC35A2 gene. The present application provides a gene panel, which can target capture the entire SLC35A2 gene related region, including exons, introns, promoters and enhancers, and carry out somatic cell variation detection, including SNVs, small Indels and SVs. The panel is used for detection of refractory epilepsy surgical brain tissue specimens, and can genetically diagnose mild cortical dysplasia with oligodendrogliosis epilepsy (MOGHE). This kind of disease is a new subtype of focal cortical dysplasia newly included by the International League Against Epilepsy in 2022. The panel has high variation detection rate and more comprehensive variation detection types.

The application discloses a brain network analysis method based on step-by-step information flow and de-redundancy, and belongs to the field of image analysis; solves the problems that a simple network building mode cannot reflect the information flow propagation process between specific regions at different levels, and information redundancy caused by the repeated existence of some edges in different high-order adjacency matrices, etc. The interaction between electrodes at the connection level is mainly captured through a step-by-step process, and the redundant information between matrices of different orders is eliminated by using a de-redundancy module. Finally, the epilepsy propagation path is successfully captured, thereby providing a reference value for surgical resection of intractable epilepsy patients.

The present invention relates to the field of epilepsy, and more specifically, discloses a clinical system for closure surgery in patients with refractory epilepsy accompanied by high shunt flow PFOs. The system comprises a patient medical record information acquisition and storage module for acquiring and storing electronic medical record data of epilepsy patients, wherein the types of electronic medical record data include sex, age at surgery, age of epilepsy onset, seizure frequency, normality of 24-hour EEG examination, and seizure duration, and the electronic medical record data includes sample data from a sample population and subject data from a subject; a patient selection module for selecting subjects who may be suitable for PFO closure surgery; and a preoperative efficacy evaluation module for evaluating the effectiveness of the subject if they undergo the PFO closure surgery. The clinical system provided by the present invention has a complete and normative evaluation system for patient selection and exclusion, and is useful for guiding the selection, decision-making, and postoperative management of epilepsy patients suitable for application of PFO closure surgery.

The application belongs to the technical field of medicine, and particularly relates to an arylalkyl azole derivative, a preparation method and application thereof. The arylalkyl azole derivative is obtained by directly connecting 4H-1,2,4-triazole-4-yl to benz[d][1,3]thiazine as aryl through a chemical bond and introducing an alkoxy group at the C6 position of the aryl. The compound of the application has a novel structure, and as a GABA_A receptor agonist, exhibits excellent anticonvulsant activity in two kinds of epilepsy models of maximum electric shock and subcutaneous pentylenetetrazole. In particular, the compound exhibits an extremely high protection index PI>10 in the subcutaneous pentylenetetrazole model, indicating that the compound has the remarkable advantages of diverse action mechanism, wide therapeutic window and low neurotoxicity, and can be used for preparing an antiepileptic drug, and is particularly suitable for the treatment of refractory epilepsy.